Komori
Share Issuance and Disposal4583Chiome Bioscience Inc.Pharmaceuticals

Notice Regarding the Monthly Exercise Status of the 23rd Stock Acquisition Rights (with Exercise Price Adjustment Clause)

In July 2026, 22,098 of the 23rd Stock Acquisition Rights were exercised, and 2,209,800 new shares were delivered. As of the end of the month, 7,137 rights (713,700 shares) remained unexercised.

Worth reading
66In focus
Scored from 1 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
2209800
Shares
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Monthly report on the exercise status of stock acquisition rights with an exercise price adjustment clause

発行・処分する株式数

Shares delivered during the month: 2,209,800 new shares; 0 transferred treasury shares

発行済株式総数

Exercise ratio subject to the monthly exercise limit: 3.25% (2,209,800 shares delivered during the month / 68,053,800 listed shares as of the payment date for the issuance)

The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.

Terms of the stock acquisition rights
Exercise price
Exercise price in July 2026: ¥63.0–¥72.7. Details of the exercise price adjustment clause and adjustment floor: Not disclosed
Number of Stock Acquisition Rights
Total number issued: 22,098 rights, stated as 16.24% of the total number issued. Unexercised balance at the end of the month preceding the target month: 29,235 rights; unexercised balance at the end of the target month: 7,137 rights
Payment date
15 December 2025 (when the stock acquisition rights were issued)
Procedures under the Corporate Code of Conduct
Report on compliance with exercise restrictions under Article 434 of the Tokyo Stock Exchange's Securities Listing Regulations and the Japan Securities Dealers Association's Rules Concerning the Handling of Third-Party Allotments
Most recent equity financing
Timing 15 December 2025 / Type Issuance of the 23rd Series Stock Acquisition Rights (with Exercise Price Adjustment Clause) / Amount Not disclosed
Details of issuance or disposal
ItemDetails
Type of issuance or disposalMonthly report on the exercise status of stock acquisition rights with an exercise price adjustment clause
Number of shares to be issued or disposed ofShares delivered during the month: 2,209,800 new shares; 0 transferred treasury shares
Payment date15 December 2025 (when the stock acquisition rights were issued)
Dilution RateExercise ratio subject to the monthly exercise limit: 3.25% (2,209,800 shares delivered during the month / 68,053,800 listed shares as of the payment date for the issuance)
Exercise priceExercise price in July 2026: ¥63.0–¥72.7. Details of the exercise price adjustment clause and adjustment floor: Not disclosed
Number of Stock Acquisition RightsTotal number issued: 22,098 rights, stated as 16.24% of the total number issued. Unexercised balance at the end of the month preceding the target month: 29,235 rights; unexercised balance at the end of the target month: 7,137 rights
Procedures under the Corporate Code of ConductReport on compliance with exercise restrictions under Article 434 of the Tokyo Stock Exchange's Securities Listing Regulations and the Japan Securities Dealers Association's Rules Concerning the Handling of Third-Party Allotments
Most recent equity financingTiming 15 December 2025 / Type Issuance of the 23rd Series Stock Acquisition Rights (with Exercise Price Adjustment Clause) / Amount Not disclosed
Items this document does not state (20)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsIntended allotteeIntended allottee's holding policyTotal number of issued sharesBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To report the monthly exercise status in July 2026 of the 23rd Stock Acquisition Rights (with an exercise price adjustment clause) issued on 15 December 2025.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Monthly Exercise Status of the 23rd Stock Acquisition Rights (with Exercise Price Adjustment Clause) | Chiome Bioscience Inc. (4583) timely disclosure | Komori